Crystagen after radiation exposure: Medical Center clinical report
Comparison in people · 2006
- What was studied
- 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
- Main finding
- In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.
Reported findings and study design
40 received Crystagen plus conventional therapy and 30 received conventional therapy alone. The reported oral regimen was one to three capsules two to three times daily for 15–20 days. Table 2 covers the low-dose radiation subgroup (20 treated, 15 comparator).
Population or model 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| CD4-positive cells in the low-dose radiation subgroup | 32.1 ± 1.8% with Crystagen vs 29.7 ± 2.4% with conventional care. Shared baseline 26.3 ± 2.4%. | The Crystagen value is marked p < 0.05 versus baseline. |
| CD3-positive cells in the low-dose radiation subgroup | 53.3 ± 2.2% with Crystagen vs 49.3 ± 2.3% with conventional care. Shared baseline 45.1 ± 2.1%. | The Crystagen value is marked p < 0.05 versus baseline. |
| IgG in the low-dose radiation subgroup | 15.2 ± 1.5 g/L with Crystagen vs 15.4 ± 1.4 g/L with conventional care. Shared baseline 15.1 ± 1.2 g/L. | The table gives no significance mark for IgG. |
The report uses a shared baseline and gives no direct between-group statistical test for these outcomes.
Source for these results ↗ · Reviewed 2026-11-16
Study limitations and source details
Study limitations
- The report gives one shared baseline column and leaves allocation and masking unspecified.
- The low-dose radiation table covers 20 treated patients and 15 conventional-care patients.
- The clinical product is insufficiently characterized to establish equivalence with synthetic EDP.
Source details
Institute report / commercial reproduction
Report reproduction, PDF pages 109–112. Methods and Tables 1–2.
Sources checked
Citation
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Originating institute; report reproduced in commercial collection. Crystagen after radiation exposure: Medical Center clinical report Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109